Search results
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Motley Fool via Yahoo Finance· 6 days agoClinical-stage biotech Editas Medicine (NASDAQ: EDIT) delivered quarterly results that fell well...
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
GuruFocus.com via Yahoo Finance· 1 day agoOn May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000...
Earnings call: Editas Medicine outlines strategic pillars for 2024 By Investing.com
Investing.com· 6 days agoEditas Medicine (NASDAQ:EDIT) has reported significant strides in its first quarter of 2024,...
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest...
Simply Wall St. via Yahoo Finance· 4 days agoEditas Medicine, Inc. (NASDAQ:EDIT) just released its latest quarterly report and things are not...
Editas Medicine First Quarter 2024 Earnings: Misses Expectations
Simply Wall St. via Yahoo Finance· 7 days agoEditas Medicine (NASDAQ:EDIT) First Quarter 2024 Results Key Financial Results Revenue: US$1.14m...
Major Improvements In Editas Medicine Inc (EDIT) Stock Need To Be Considered – Stocks Register
Stocks Register· 7 days agoEditas Medicine Inc (NASDAQ:EDIT) price on Wednesday, May 09, fall -11.36% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $5.03. A look at the ...
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Zacks via Yahoo Finance· 7 days agoEditas Medicine, Inc. EDIT incurred a loss of 76 cents per share in the first quarter of 2024, wider...
Editas Medicine Inc (EDIT) (Q1 2024) Earnings Call Transcript Hi
Guru Focus· 7 days agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. Completed enrollment in the adult cohort of the Ruby clinical trial and initiated enrollment ...
How Editas 'dragged' Linda Burkly over as CSO after 37 years at Biogen
FierceBiotech· 6 days agoLinda Burkly, Ph.D., was 37 years into a career at Biogen when Editas Medicines CEO Gilmore...
Gene Editing Breakthrough: CRISPR Improves Vision in Clinical Trial
SciTechDaily· 2 days agoMass Eye and Ear researchers say their findings support continued research and clinical trials of...